2 Results for "

non-HDL-C

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "non-HDL-C" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-P99822
CAS No.: 2361290-85-7
Synonyms: SHR-1209

Target:  

PCSK9

Research Areas:  

Metabolic Disease

Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .
loading...
    loading...
Cat. No.: HY-18778C
CAS No.: 866399-89-5
Synonyms: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium
Target:  

CETP PCSK9 LDLR

Research Areas:  

Inflammation/Immunology

Obicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia .
loading...
    loading...